Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001751 | 0.89 | POLB (0.50) | ALDH1A1HTTPOLBKMT2AGAA | |
| SCHEMBL29643230 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HTTPOLBKMT2AGAA | |
| SCHEMBL83222 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HTTPOLBKMT2AGAA | |
| SCHEMBL6193007 | 0.87 | ALDH1A1 (0.49) | ALDH1A1HTTPOLBKMT2AGAA | |
| SCHEMBL30595375 | 0.85 | POLB (0.50) | ALDH1A1HTTPOLBKMT2AGAA | |
| SCHEMBL30022123 | 0.80 | POLB (0.54) | ALDH1A1POLBKMT2AGAAHPGD | |
| SCHEMBL28420408 | 0.74 | ERCC1 (0.55) | ALDH1A1KMT2AHPGDHSD17B10CYP1A2 | |
| SCHEMBL28302109 | 0.73 | ALDH1A1 (0.55) | ALDH1A1KMT2AHPGDHSD17B10CYP1A2 | |
| SCHEMBL29429710 | 0.72 | ERCC1 (0.52) | ALDH1A1HTTPOLBKMT2ANPC1 | |
| SCHEMBL9579358 | 0.72 | POLB (0.45) | ALDH1A1HTTPOLBKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2018-09-13 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-8796436-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130211063-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8507661-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
| US-20180258427-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | ALDH1A1 1587/4885HTT 1913/4885POLB 1262/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | ALDH1A1 1745/4885HTT 1329/4885POLB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.